The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...
Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...
Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as many therapeutic antibodies. Therapeutic antibodies are widely used for the treatment of ...
Growing market interest in biosimilars in 2024 was also marked by significant regulatory, legal, and commercial developments concerning biologics and biosimilars. Here, we review developments from ...
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback